Literature DB >> 17151036

Modelling the effectiveness of chlamydia screening in England.

K M E Turner1, E J Adams, D S Lamontagne, L Emmett, K Baster, W J Edmunds.   

Abstract

BACKGROUND: Several developed countries have initiated chlamydia screening programmes. Screening for a sexually transmitted infection has both direct individual and indirect population-wide effects. Mathematical models can incorporate these non-linear effects and estimate the likely impact of different screening programmes and identify areas where more data are needed.
METHODS: A stochastic, individual based dynamic network model, parameterised from UK screening studies and data on sexual behaviour and chlamydia epidemiology, was used to investigate the likely impact of opportunistic screening on chlamydia prevalence. Three main strategies were considered for <25 year olds: (1) annual offer to women; (2) annual offer to women or if changed partner within last 6 months; (3) annual offer to men and women. Sensitivity analyses were performed for key screening parameters including uptake rate, targeted age range, percentage of partners notified, and screening interval.
RESULTS: Under strategy 1, continuous opportunistic screening of women <25 years of age is expected to reduce the population prevalence by over 50% after 5 years. Prevalence is also expected to decrease in unscreened older women and in men. For all three strategies screening those aged over 25 results in small additional reductions in prevalence. Including men led to a faster and greater reduction in overall prevalence, but involved approximately twice as many tests as strategy 1 and 10% more than strategy 2. The frequency of attendance at healthcare sites limits the number of opportunities to screen and the effect of changing the screening interval.
CONCLUSIONS: The model suggests that continuous opportunistic screening at high uptake rates could significantly reduced chlamydia prevalence within a few years. Opportunistic programmes depend on regular attendance at healthcare providers, but there is a lack of high quality data on patterns of attendance. Inequalities in coverage may result in a less efficient and less equitable outcome.

Entities:  

Mesh:

Year:  2006        PMID: 17151036      PMCID: PMC2563876          DOI: 10.1136/sti.2005.019067

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  27 in total

1.  Performance and cost-effectiveness of selective screening criteria for Chlamydia trachomatis infection in women. Implications for a national Chlamydia control strategy.

Authors:  J M Marrazzo; C L Celum; S D Hillis; D Fine; S DeLisle; H H Handsfield
Journal:  Sex Transm Dis       Date:  1997-03       Impact factor: 2.830

2.  The correct approach to modelling and evaluating chlamydia screening.

Authors:  T Roberts; S Robinson; P Barton; S Bryan; A McCarthy; J Macleod; M Egger; N Low
Journal:  Sex Transm Infect       Date:  2004-08       Impact factor: 3.519

Review 3.  Genital chlamydial infections: epidemiology and reproductive sequelae.

Authors:  W Cates; J N Wasserheit
Journal:  Am J Obstet Gynecol       Date:  1991-06       Impact factor: 8.661

4.  The role of sexual partnership networks in the epidemiology of gonorrhea.

Authors:  A C Ghani; J Swinton; G P Garnett
Journal:  Sex Transm Dis       Date:  1997-01       Impact factor: 2.830

Review 5.  Chlamydia trachomatis infections: progress and problems.

Authors:  W E Stamm
Journal:  J Infect Dis       Date:  1999-03       Impact factor: 5.226

6.  Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics. A cost-effectiveness analysis of three strategies.

Authors:  M R Howell; T C Quinn; C A Gaydos
Journal:  Ann Intern Med       Date:  1998-02-15       Impact factor: 25.391

Review 7.  Chlamydia trachomatis in the United Kingdom: a systematic review and analysis of prevalence studies.

Authors:  E J Adams; A Charlett; W J Edmunds; G Hughes
Journal:  Sex Transm Infect       Date:  2004-10       Impact factor: 3.519

8.  Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis.

Authors:  Delphine Hu; Edward W Hook; Sue J Goldie
Journal:  Ann Intern Med       Date:  2004-10-05       Impact factor: 25.391

9.  Cost-effectiveness analysis of screening adolescent males for Chlamydia on admission to detention.

Authors:  Diane R Blake; Charlotte A Gaydos; Thomas C Quinn
Journal:  Sex Transm Dis       Date:  2004-02       Impact factor: 2.830

10.  Tubal infertility: serologic relationship to past chlamydial and gonococcal infection. World Health Organization Task Force on the Prevention and Management of Infertility.

Authors: 
Journal:  Sex Transm Dis       Date:  1995 Mar-Apr       Impact factor: 2.830

View more
  36 in total

1.  Resource Allocation for Epidemic Control Across Multiple Sub-populations.

Authors:  Ciara E Dangerfield; Martin Vyska; Christopher A Gilligan
Journal:  Bull Math Biol       Date:  2019-02-26       Impact factor: 1.758

2.  Racial/Ethnic Disparities in the Lifetime Risk of Chlamydia trachomatis Diagnosis and Adverse Reproductive Health Outcomes Among Women in King County, Washington.

Authors:  Laura C Chambers; Christine M Khosropour; David A Katz; Julia C Dombrowski; Lisa E Manhart; Matthew R Golden
Journal:  Clin Infect Dis       Date:  2018-08-01       Impact factor: 9.079

3.  Incidence and reinfection rates of genital chlamydial infection among women aged 16-24 years attending general practice, family planning and genitourinary medicine clinics in England: a prospective cohort study by the Chlamydia Recall Study Advisory Group.

Authors:  D Scott Lamontagne; Kathleen Baster; Lynsey Emmett; Tom Nichols; Sarah Randall; Louise McLean; Paula Meredith; Veerakathy Harindra; Jean M Tobin; Gillian S Underhill; W Graham Hewitt; Jennifer Hopwood; Toni Gleave; Ajit K Ghosh; Harry Mallinson; Alisha R Davies; Gwenda Hughes; Kevin A Fenton
Journal:  Sex Transm Infect       Date:  2006-10-18       Impact factor: 3.519

4.  Management of epididymo-orchitis in primary care: results from a large UK primary care database.

Authors:  Amanda Nicholson; Greta Rait; Tarita Murray-Thomas; Gwenda Hughes; Catherine H Mercer; Jackie Cassell
Journal:  Br J Gen Pract       Date:  2010-10       Impact factor: 5.386

5.  Cost-Effectiveness of Opt-Out Chlamydia Testing for High-Risk Young Women in the U.S.

Authors:  Kwame Owusu-Edusei; Karen W Hoover; Thomas L Gift
Journal:  Am J Prev Med       Date:  2016-03-04       Impact factor: 5.043

6.  The cost effectiveness of opportunistic chlamydia screening in England.

Authors:  Elisabeth J Adams; Katherine M E Turner; W John Edmunds
Journal:  Sex Transm Infect       Date:  2007-07       Impact factor: 3.519

7.  The cost-effectiveness of screening men who have sex with men for rectal chlamydial and gonococcal infection to prevent HIV Infection.

Authors:  Harrell W Chesson; Kyle T Bernstein; Thomas L Gift; Julia L Marcus; Sharon Pipkin; Charlotte K Kent
Journal:  Sex Transm Dis       Date:  2013-05       Impact factor: 2.830

8.  Chlamydia screening in England: a qualitative study of the narrative behind the policy.

Authors:  Jessica Sheringham; Paula Baraitser; Ian Simms; Graham Hart; Rosalind Raine
Journal:  BMC Public Health       Date:  2012-04-30       Impact factor: 3.295

9.  Effectiveness of yearly, register based screening for chlamydia in the Netherlands: controlled trial with randomised stepped wedge implementation.

Authors:  Ingrid V F van den Broek; Jan E A M van Bergen; Elfi E H G Brouwers; Johannes S A Fennema; Hannelore M Götz; Christian J P A Hoebe; Rik H Koekenbier; Mirjam Kretzschmar; Eelco A B Over; Boris V Schmid; Lydia L Pars; Sander M van Ravesteijn; Marianne A B van der Sande; G Ardine de Wit; Nicola Low; Eline L M Op de Coul
Journal:  BMJ       Date:  2012-07-05

10.  Delivery of chlamydia screening to young women requesting emergency hormonal contraception at pharmacies in Manchester, UK: a prospective study.

Authors:  Loretta Brabin; Grace Thomas; Mark Hopkins; Karen O'Brien; Stephen A Roberts
Journal:  BMC Womens Health       Date:  2009-03-26       Impact factor: 2.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.